Looking at Shionogi & Co., Ltd. (OTCMKTS:SGIOY) and Saipem (OTCMKTS:SAPMF)

Shionogi & Co., Ltd. (OTCMKTS:SGIOY – Get Free Report) and Saipem (OTCMKTS:SAPMF – Get Free Report) are both medical companies, but which is the superior investment? We’ll compare the two businesses based on their institutional ownership strength, profitability, earnings, risk, valuation, dividends and analyst recommendations.

Earnings and Rating

This table compares Shionogi & Co., Ltd. and Saipem’s revenue, earnings per share and valuation.

Shionogi & Co., Ltd. has higher earnings but lower revenue than Saipem.

return

This table compares Shionogi & Co., Ltd. and Saipem’s net margins, return on equity and return on assets.

Analyst ratings

This is a breakdown of recent ratings and price targets for Shionogi & Co., Ltd. and Saipem, as reported by MarketBeat.com.

Insider and institutional ownership

1.9% of Shionogi & Co., Ltd. shares are owned by institutional investors. Strong institutional ownership is an indication that big money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk and volatility

Shionogi & Co., Ltd. has a beta of 0.22, indicating that its stock price is 78% less volatile than the S&P 500. Comparatively, Saipem has a beta of 1.3, indicating the fact that its share price is 30% more volatile than the S&P. 500.

Summary

Shionogi & Co., Ltd. beats Saipem on 6 of the 8 factors compared between the two stocks.

About Shionogi & Co., Ltd.

(Get a free report)

Shionogi & Co., Ltd. is engaged in the research, development, manufacture and distribution of pharmaceuticals, diagnostic reagents and medical devices in Japan. It offers Fetroja, a multidrug resistant for the treatment of gram-negative bacterial infections; Cabenuva and Apretude an anti-HIV and prophylactic HIV drug; Xocova an oral medicine for the treatment of COVID-19; Finibax a carbapenem antibiotic; Xofluza, an antiviral flu drug; and Tivicay, an anti-HIV drug. Also developing S-872600 a nasal flu vaccine; S-875670 a nasal COVID-19 vaccine; S-540956 a nucleic acid adjuvant; S-554110 a nontuberculous mycobacterial infection; S-337395 for RSV infections; S-892216 for COVID-19 therapies; Holorophym for invasive aspergillosis; cefiderocol for aerobic gram-negative bacterial infections and infectious diseases; S-268019 a prophylactic COVID-19 vaccine; S-268019 a prophylactic vaccine for COVID-19; ensitrelvir for the treatment and prevention of COVID-19; baloxavir for influenza virus infection; S-365598 for HIV infection; and S-555739 to suppress worsening of COVID-19. In addition, the company is developing S-540956 for the nucleic acid adjuvant; S-109802 for post-stroke spasticity; S-151128 for chronic pain; S-588210 and S-531011 for solid tumor; S-309309 for obesity; BPN14770 for Alzheimer’s disease and fragile X syndrome; S-588410 for bladder cancer; S-488210 for squamous cell carcinoma of the head and neck; S-005151 for acute ischemic stroke and epidermolysis bullosa; Rizmoic for opioid-induced constipation; ADR-001 for decompensated liver cirrhosis; S-222611 for malignant tumor; S-812217 for depression; GRT7039 for pain associated with osteoarthritis of the knee; SDT-001 for inattentive ADHD; S-588410 for esophageal cancer; SR-0379 for skin ulcer; and S-723595 for type 2 diabetes. The company was formerly known as Shionogi Shoten Co., Ltd. and changed its name to Shionogi & Co., Ltd. in 1943. Shionogi & Co., Ltd. was founded in 1878 and is based in Osaka, Japan.

About Saipem

(Get a free report)

Saipem SpA provides energy and infrastructure solutions worldwide. The company operates through Offshore Engineering & Construction (E&C), Onshore Engineering & Construction and Offshore Drilling divisions. Provides subsea field development and pipeline layout; installation and erection of offshore structures; and engineering, implementation, installation, maintenance, modification and decommissioning activities. The company also offers biorefineries, geothermal energy, carbon capture, wind and solar energy, waste to energy and renewables and green technologies; high-speed rail; premium services, engineering and intelligent maintenance; and offshore and onshore services. In addition, the company provides integrated procurement, project management, construction and engineering services for the energy industry and public markets. Saipem SpA was founded in 1957 and is headquartered in Milan, Italy.

Get daily news and reviews for Shionogi & Co. Ltd – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Shionogi & Co. Ltd. and affiliates with MarketBeat.com’s FREE daily email newsletter.